Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients

Mild Cognitive Impairment Clinical Trial

Official title:

Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00202540
• Other study ID #: CL2-18986-009
• Status: Terminated
• Phase: Phase 2
• First received: September 12, 2005
• Last updated: March 19, 2018
• Start date: June 2005
• Est. completion date: March 29, 2006

Study information

• Verified date: March 2018
• Source: Servier
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate a long term efficacy of S18986 versus placebo on episodic memory performance in patients with MCI

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: March 29, 2006
• Est. primary completion date: March 29, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Memory complaint

• Acetylcholinesterase inhibitors stopped at least 3 months before selection

Exclusion Criteria:

• Dementia

• Parkinson's disease

• Vascular disorder

• Depression

• Epilepsy

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Drug:
• S18986

Locations

Country	Name	City	State
France	Hôpital la Grave-Casselardit	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Recherches Internationales Servier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Episodic memory
Secondary	Other cognitive domains, activities of daily living, global impression of change, MRI, safety.

External Links

•   Results summary